Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open‐label study

Abstract

Adalimumab is well tolerated and appears to be effective in maintaining clinical remission in patients with Crohn's disease and lost response or intolerance to infliximab.